Company: BIAF
Filing Date: 2025-04-15
Form Type: DRS
Source: 0001641172-25-004915
Chunk: 14

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-04-15
Form: DRS
Chunk 14
---
. |

| ● | PPLS                                                                                           
 may be unable to maintain equipment or generate revenue when its equipment is not operational. |

| ● | If                                                                                         
 our sole laboratory facility becomes damaged or inoperable, loses its accreditation, or is 
 required to vacate the facility, PPLS’ ability to sell its products or provide diagnostic  
 assays and pursue its research and development efforts may be jeopardized.                 |

| ● | Disruption                                                                                 
 in the commercial courier delivery services used by PPLS to transport sputum samples could 
 harm its business.                                                                         |

| ● | Security                                                                                   
 breaches, data loss, and other disruptions could compromise sensitive information of PPLS’ 
 business.                                                                                  |

| 3 |

| ● | If                                                                                              
 PPLS uses hazardous chemicals in a manner that causes injury, PPLS could be liable for damages. |

| ● | If                                                                                       
 PPLS is unable to successfully scale its operations to support demand its business could 
 suffer.                                                                                  |

| ● | PPLS                                                                                    
 must dedicate substantial time and resources to its complex billing process to be paid. |

| ● | Delays                                                                                       
 of third-party billing and collection providers and an in-house billing function to transmit 
 claims to payors could have an adverse effect on PPLS.                                       |

Risks Related to Intellectual Property Rights

| ● | If                                                                                        
 we fail to comply with our obligations imposed by any intellectual property licenses with 
 third parties that we may need in the future, we could lose rights that are important to  
 our business.                                                                             |

| ● | We                                                                                       
 may need to obtain licenses of third-party technology that may not be available to us or 
 available to us on reasonable terms.                                                     |

| ● | Our                                                                      
 competitive position depends on protection of our intellectual property. |

| ● | Diagnostic                                                                         
 tests and therapeutic products we develop could be subject to infringement claims. |

| ● | We                                                                               
 may become involved in lawsuits to protect or enforce our intellectual property. |

| ● | If                                                                                         
 we are unable to protect our trade secrets, our business and competitive position could be 
 harmed.                                                                                    |

| ● | Changes                                                                             
 in patent law could impair our ability to protect our tests and product candidates. |

| ● | Our                                                                                                 
 patent protection could be reduced or eliminated for non-compliance with governmental requirements. |

| ● | Patent                                                                                     
 terms may be inadequate to protect our diagnostic tests or therapeutic product candidates. |

| ● | Issued